BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15534571)

  • 21. Low risk of pelvic inflammatory disease in young never-pregnant women using Gravigard.
    Larsson B; Hagström B; Viberg L; Anker C; Hamberger L; Lindhe BA
    Contraception; 1979 Sep; 20(3):291-5. PubMed ID: 509955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
    Cohen R; Sheeder J; Arango N; Teal SB; Tocce K
    Contraception; 2016 Feb; 93(2):178-83. PubMed ID: 26475368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Risks of the IUD for young women].
    Dukkers van Emden DM; van der Maas PJ
    Ned Tijdschr Geneeskd; 1984 Jul; 128(27):1272-6. PubMed ID: 6462275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levonorgestrel Intrauterine Device Use for Medical Indications in Nulliparous Adolescents and Young Adults.
    Schwartz BI; Alexander M; Breech LL
    J Adolesc Health; 2021 Feb; 68(2):357-363. PubMed ID: 32646831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obstetrician-gynecologists and contraception: practice and opinions about the use of IUDs in nulliparous women, adolescents and other patient populations.
    Luchowski AT; Anderson BL; Power ML; Raglan GB; Espey E; Schulkin J
    Contraception; 2014 Jun; 89(6):572-7. PubMed ID: 24679477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The TCu-380A (AG), MLCu375, and Nova-T IUDs and the IUD daily releasing 20 micrograms levonorgestrel--four pillars of IUD contraception for the nineties and beyond?
    Chi IC
    Contraception; 1993 Apr; 47(4):325-47. PubMed ID: 8508663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The intrauterine device in the present and future.
    Rivera R; Chi IC; Farr G
    Curr Opin Obstet Gynecol; 1993 Dec; 5(6):829-32. PubMed ID: 8286697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complications associated with IUD use in a family practice setting.
    Lewis RD; Shank C
    J Fam Pract; 1979 Jan; 8(1):47-52. PubMed ID: 759549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Health risks in intrauterine contraception].
    Randić L; Haller H
    Jugosl Ginekol Perinatol; 1989; 29(5-6):181-6. PubMed ID: 2640266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.
    Nilsson CG; Allonen H; Diaz J; Luukkainen T
    Fertil Steril; 1983 Feb; 39(2):187-92. PubMed ID: 6401636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pelvic inflammatory disease in intrauterine device users.
    Beerthuizen RJ
    Eur J Contracept Reprod Health Care; 1996 Sep; 1(3):237-43. PubMed ID: 9678122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A national study to monitor the safety of IUCD use.
    Richardson A; Paul C
    Contraception; 1993 Apr; 47(4):359-66. PubMed ID: 8508665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pelvic inflammatory disease among women using copper IUDs, Progestasert, oral contraceptive pills or vaginal contraceptive pills: a 4-year prospective investigation.
    Larsson B; Rodau S; Patek E
    Contracept Deliv Syst; 1981 Jul; 2(3):237-42. PubMed ID: 12278910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statement on intrauterine devices (IUDs).
    International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
    IPPF Med Bull; 1987 Dec; 21(6):3-5. PubMed ID: 12268853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
    Eisenberg DL; Schreiber CA; Turok DK; Teal SB; Westhoff CL; Creinin MD;
    Contraception; 2015 Jul; 92(1):10-6. PubMed ID: 25934164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrauterine contraceptive device use and pelvic inflammatory disease.
    Kaufman DW; Shapiro S; Rosenberg L; Monson RR; Miettinen OS; Stolley PD; Slone D
    Am J Obstet Gynecol; 1980 Jan; 136(2):159-62. PubMed ID: 7352496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current concepts on the use of IUDs.
    McCarthy T
    Singapore Med J; 1989 Aug; 30(4):390-2. PubMed ID: 2814545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IUDs: current perspectives.
    Hepburn S
    Curr Ther (Seaforth); 1994 Oct; 35(10):49-55. PubMed ID: 12319352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrauterine devices: an update.
    Hardeman J; Weiss BD
    Am Fam Physician; 2014 Mar; 89(6):445-50. PubMed ID: 24695563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.